AlphaMark Advisors’s Novavax NVAX Stock Holding History

AlphaMark Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35	Closed	–	–	755
2023 Q2	$0	Hold	35	–	–	﹤0.01%	634
2023 Q1	$0	Hold	35	–	–	﹤0.01%	646
2022 Q4	$0	Hold	35	–	–	﹤0.01%	684
2022 Q3	$1K	Hold	35	–	–	﹤0.01%	650
2022 Q2	$2K	Hold	35	–	–	﹤0.01%	551
2022 Q1	$3K	Hold	35	–	–	﹤0.01%	522
2021 Q4	$5K	Hold	35	–	–	﹤0.01%	456
2021 Q3	$7K	Hold	35	–	–	﹤0.01%	439
2021 Q2	$7K	Hold	35	–	–	﹤0.01%	432
2021 Q1	$6K	Hold	35	–	–	﹤0.01%	425
2020 Q4	$4K	Hold	35	–	–	﹤0.01%	440
2020 Q3	$4K	Buy	+35	New	+$4.26K	﹤0.01%	450

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AlphaMark Advisors's NVAX Position: Q3 2023 in Review

AlphaMark Advisors sold out of Novavax (NVAX) in Q3 2023, closing a stake of 35 shares.

AlphaMark Advisors first reported a position in NVAX in Q3 2020 and held it in 12 quarters. The position peaked at $7K in Q3 2021. 225 funds tracked by Wall St. Rank hold NVAX as of Q3 2023.

AlphaMark Advisors reported no remaining Novavax position as of Q3 2023 after selling out during the quarter.
AlphaMark Advisors sold 35 Novavax shares in Q3 2023.
AlphaMark Advisors first reported a position in Novavax in Q3 2020 and held it in 12 quarters.
AlphaMark Advisors's Novavax position peaked at $7K in Q3 2021.
225 funds tracked by Wall St. Rank held Novavax as of Q3 2023.

Based on AlphaMark Advisors's 13F filing for Q3 2023, filed 31 Oct 2023.